ABSTRACT:
Molnupiravir is an anti-viral medication. A new stability indicating RP-UFLC method was proposed for the estimation of Molnupiravir in capsules. Shimadzu Model CBM-20A/20 Alite UFLC system with PDA detector and Zorbox C18 column were used for the chromatographic study. Mobile phase mixture consisting of 0.1% Acetic acid: Acetonitrile (35:65, v/v) with a flow rate 0.8 ml/min was chosen for the chromatographic elution of Molnupiravir (Detection wavelength 245 nm). The method was linear over the concentration range 2.0-100 mg/ml with linear regression equation, y = 29137x + 3455.8 (R² = 0.9999). The LOD and LOQ were found to be 0.4574 mg/ml and 1.548 mg/ml respectively. Forced degradation studies were performed and the method was validated as per ICH guidelines.
Cite this article:
Asia, Revu Baby Nalanda. Development and validation of a new stability indicating RP-UFLC method for the quantification of Molnupiravir. Research Journal of Pharmacy and Technology. 2025;18(4):1680-7. doi: 10.52711/0974-360X.2025.00241
Cite(Electronic):
Asia, Revu Baby Nalanda. Development and validation of a new stability indicating RP-UFLC method for the quantification of Molnupiravir. Research Journal of Pharmacy and Technology. 2025;18(4):1680-7. doi: 10.52711/0974-360X.2025.00241 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-4-32
REFERENCES:
1. Singh AK, Singh A, Singh R, Misra A. Molnupiravir in COVID-19: A systematic review of literature. Diabetes and Metabolic Syndrome. 2021; 15 (6): 102329.
2. Kabinger F., Stiller C., Schmitzová J., Dienemann C., Kokic G., Hillen H.S., Höbartner C., Cramer P. Mechanism of Molnupiravir-induced SARS-CoV-2 mutagenesis. Nat. Struct. Mol. Biol. 2021; 28: 740-746.
3. Pritam Jain, Manali Bhamare, Sanjay Surana. Quantitative estimation of Molnupiravir by UV- spectrophotometric method. International Journal of Pharmaceutical Chemistry and Analysis. 2022; 9(1): 35-39.
4. Aboras, S.I., Megahed, A.A., El-Yazbi, Fawzy and Hadir M Maher. White targeted chromatographic screening method of Molnupiravir and its metabolite with degradation kinetics characterization and in-silico toxicity. Scientific Reports. 2023; 13: 17919.
5. Gandu Sravanthi, Kumara Swamy Gandla and Lalitha Repudi. New analytical method development and validation for estimation of Molnupiravir in bulk and tablet dosage form by RP-HPLC method. Cellular, Molecular and Biological Reports 2023; 3(3): 130-136.
6. Tuba Reçber , Selin Seda Timur , Sevilay Erdoğan Kablan , Fatma Yalçın , Tutku Ceren Karabulut , R Neslihan Gürsoy , Hakan Eroğlu , Sedef Kır , Emirhan Nemutlu. A stability indicating RP-HPLC method for determination of the COVID-19 drug Molnupiravir applied using nano formulations in permeability studies. J Pharm Biomed Anal. 2022; 214: 114693.
7. Ravi Kumar G, Suman Babua B, Rama Rao R, Megha Vardhan, V and VDN Kumar Abbaraju. Method development and validation of a specific stability indicating RP-HPLC method for Molnupiravir API. Journal of Pharmaceutical Research and Innovation. 2021; 33: 3026-3035.
8. Annadi AM, El Zahar NM, El-Din A Abdel-Sattar N, Mohamed EH, Mahmoud SA, Attia MS. Development and validation of Molnupiravir assessment in bulk powder and pharmaceutical formulation by the RP-HPLC-UV method. RSC Adv 2022; 12(53): 34512-34519.
9. Hebatallah A. Wagdy. A newly developed and validated environmentally friendly RP-HPLC stability indicating method for the COVID-19 antiviral Molnupiravir: Application to degradation kinetics structure suggestion using LC-MS and the effect on viable cells of the major degradation products. Microchemical Journal, 199; 2024: 109980.
10. Komarov T, Karnakova P, Archakova O, Shchelgacheva D, Bagaeva N, Popova M, Karpova P, Zaslavskaya K, Bely P, Shohin I. Development and validation of a high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS) method for quantification of major molnupiravir metabolite (β-D-N4-hydroxycytidine) in human plasma. Biomedicines. 2023; 11(9): 2356.
11. Alieu Amara , Sujan Dilly Penchala, Laura Else, Colin Hale, Richard FitzGerald, Lauren Walker, Rebecca Lyons, Tom Fletcher and Saye Khoo. The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ss-d-N4-hydroxycytidine in human plasma and saliva. J. Pharm. Biomed. Anal. 2021; 206: 114356.
12. Jain S, Giri S, Sharma N and Shah RP. LC and LC-HRMS studies on stability behavior of Molnupiravir an anti-COVID 19 drug. J. Liq. Chromatogr. Relat. Technol. 2022; 44(15): 1-10.
13. ICH, Validation of analytical procedures: Text and methodology Q2 (R1). International Conference on Harmonization. Geneva; 2005.
14. ICH, Stability Testing of New Drug Substances and Products Q1A (R2). International Conference on Harmonization. Geneva; 2003.